MA42701B1 - Compositions d'insuline à action rapide - Google Patents

Compositions d'insuline à action rapide

Info

Publication number
MA42701B1
MA42701B1 MA42701A MA42701A MA42701B1 MA 42701 B1 MA42701 B1 MA 42701B1 MA 42701 A MA42701 A MA 42701A MA 42701 A MA42701 A MA 42701A MA 42701 B1 MA42701 B1 MA 42701B1
Authority
MA
Morocco
Prior art keywords
acting insulin
rapid acting
insulin compositions
insulin
analogue
Prior art date
Application number
MA42701A
Other languages
English (en)
Other versions
MA42701A (fr
Inventor
Michael Patrick Akers
Ranajoy Majumdar
Chi A Nguyen
Chad D Paavola
Virender Kumar Sarin
Nanette Elizabeth Schulte
Michael Edward Christe
Thomas Andrew Hardy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57003563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42701(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA42701A publication Critical patent/MA42701A/fr
Publication of MA42701B1 publication Critical patent/MA42701B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une composition pharmaceutique d'insuline humaine ou d'analogue d'insuline, qui comprend du citrate, du tréprostinil et des agents de stabilisation, qui a une action pharmacocinétique et/ou pharmacodynamique plus rapide que des formulations commerciales de produits analogues d'insuline existants, et qui est stable pour une utilisation commerciale.
MA42701A 2015-08-27 2016-08-19 Compositions d'insuline à action rapide MA42701B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210469P 2015-08-27 2015-08-27
PCT/US2016/047723 WO2017034956A1 (fr) 2015-08-27 2016-08-19 Compositions d'insuline à action rapide

Publications (2)

Publication Number Publication Date
MA42701A MA42701A (fr) 2018-07-04
MA42701B1 true MA42701B1 (fr) 2023-01-31

Family

ID=57003563

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42701A MA42701B1 (fr) 2015-08-27 2016-08-19 Compositions d'insuline à action rapide

Country Status (38)

Country Link
US (3) US9901623B2 (fr)
EP (2) EP3340966B1 (fr)
JP (2) JP6359780B2 (fr)
KR (1) KR102018998B1 (fr)
CN (1) CN107920992B (fr)
AR (2) AR105712A1 (fr)
AU (1) AU2016310475B2 (fr)
CA (1) CA2994427C (fr)
CL (1) CL2018000503A1 (fr)
CO (1) CO2018002026A2 (fr)
CR (1) CR20180118A (fr)
DK (1) DK3340966T3 (fr)
DO (1) DOP2018000059A (fr)
EA (1) EA033396B1 (fr)
EC (1) ECSP18014922A (fr)
ES (1) ES2928664T3 (fr)
FI (1) FI3340966T3 (fr)
HR (1) HRP20221367T1 (fr)
HU (1) HUE060626T2 (fr)
IL (1) IL256939B (fr)
JO (1) JO3749B1 (fr)
LT (1) LT3340966T (fr)
MA (1) MA42701B1 (fr)
MD (1) MD3340966T2 (fr)
MX (1) MX379267B (fr)
MY (1) MY195781A (fr)
NZ (1) NZ739338A (fr)
PE (1) PE20180782A1 (fr)
PH (1) PH12018500422B1 (fr)
PL (1) PL3340966T3 (fr)
PT (1) PT3340966T (fr)
RS (1) RS63731B1 (fr)
SV (1) SV2018005643A (fr)
TN (1) TN2018000056A1 (fr)
TW (1) TWI614025B (fr)
UA (1) UA120142C2 (fr)
WO (1) WO2017034956A1 (fr)
ZA (1) ZA201800511B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
AR102869A1 (es) * 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP4265296A3 (fr) 2016-09-29 2023-12-20 Arecor Limited Composition pharmaceutique comprenant des composés de l'insuline
CA3065308C (fr) * 2017-06-01 2022-05-17 Eli Lilly And Company Compositions d'insuline a action rapide
WO2019050749A1 (fr) 2017-09-08 2019-03-14 Eli Lilly And Company Combinaisons pharmaceutiques comprenant de l'insuline et au moins un agent sélectionné parmi le méloxicam, le bromfénac sodique, l'acide acétylsalicylique, l'acide salicylique et le paracétamol
EP3773473B1 (fr) * 2018-04-04 2026-07-01 Arecor Limited Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
EP3773474B1 (fr) * 2018-04-04 2026-01-07 Arecor Limited Système de pompe à perfusion médicale pour l'administration d'un composé d'insuline
JP7465813B2 (ja) * 2018-04-04 2024-04-11 アレコル リミテッド インスリン化合物の送達のための医療用注入ポンプシステム
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
CN112739679B (zh) * 2018-09-18 2024-03-12 伊莱利利公司 曲前列环素的特丁胺盐
CN114096269B (zh) * 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
CN115697379A (zh) * 2020-06-30 2023-02-03 江苏恒瑞医药股份有限公司 速效胰岛素组合物及其医药用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
EP0018609B1 (fr) 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Solutions aqueuses de protéines, stables à la dénaturation, procédé pour leur fabrication et leur utilisation
ZA821243B (en) * 1981-03-10 1983-01-26 Novo Industri As Stabilized insulin preparation and method for their production
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK503386D0 (da) * 1986-10-20 1986-10-20 Novo Industri As Peptidpraeparater
ES2053723T3 (es) 1987-02-25 1994-08-01 Novo Nordisk As Nuevos derivados de insulina.
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
JPH10251146A (ja) 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
JP2002535287A (ja) 1999-01-26 2002-10-22 イーライ・リリー・アンド・カンパニー 単分散性６量体のアシル化されたインスリンアナログ製剤
JP2003514014A (ja) 1999-11-15 2003-04-15 ティー ガンガル，ハナマラディ 静脈注入のためのブドウ糖およびインスリン含有液体配合物
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003094956A1 (fr) 2002-05-07 2003-11-20 Novo Nordisk A/S Preparations solubles comprenant de l'insuline monomere et de l'insuline acylee
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20050043391A1 (en) * 2003-07-17 2005-02-24 Fong Benson M. Combination therapies for treatment of hypertension and complications in patients with diabetes or metabolic syndrome
CN1917866B (zh) * 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物，或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
EP2106790B1 (fr) 2004-03-12 2012-10-24 Biodel, Inc. Compositions d'alimentation de médicament à action rapide
DE602005020269D1 (de) * 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
WO2006082204A1 (fr) * 2005-02-02 2006-08-10 Novo Nordisk A/S Derives d'insuline
ES2435522T3 (es) * 2005-02-02 2013-12-20 Novo Nordisk A/S Derivados de insulina
US20070086952A1 (en) 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
AU2006294565A1 (en) * 2005-09-30 2007-04-05 Perlegen Sciences, Inc. Methods and compositions for screening and treatment of disorders of blood glucose regulation
DE102006047613A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Peristaltische Mikropumpe mit wechselbarem Pumpenkopf
DE102006047538A1 (de) * 2006-10-07 2008-04-10 Sanofi-Aventis Deutschland Gmbh Medikamentendosiersystem mittels Mikropumpe
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー／エス インスリン誘導体を含有する薬学的製剤
CA2697057A1 (fr) * 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapie pour complications du diabete
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US9387033B2 (en) 2008-08-28 2016-07-12 Roche Diabetes Care, Inc. Device and method for enhanced subcutaneous insulin absorption
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
FR2943538B1 (fr) 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
ES2543705T3 (es) 2009-06-26 2015-08-21 Novo Nordisk A/S Preparación que contiene insulina, nicotinamida y arginina
KR101701943B1 (ko) 2009-11-13 2017-02-02 도레이 카부시키가이샤 당뇨병의 치료 또는 예방약
CA2805031A1 (fr) 2010-07-07 2012-01-12 Biodel, Inc. Compositions et procedes pour la modulation de la pharmacocinetique et de la pharmacodynamie de l'insuline
KR20140030125A (ko) 2010-12-14 2014-03-11 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
US20130022592A1 (en) 2011-06-17 2013-01-24 Daniel Edward Vaughn Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
JP5912426B2 (ja) * 2011-11-07 2016-04-27 ヤマハ発動機株式会社 リニアコンベア
SG11201403714TA (en) 2011-12-30 2014-07-30 Halozyme Inc Ph20 polypeptide variants, formulations and uses thereof
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
US20150065423A1 (en) * 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
CA2936563A1 (fr) 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Formulations d'insuline a action rapide et systemes d'administration pharmaceutique
WO2015120457A1 (fr) * 2014-02-10 2015-08-13 Biodel Inc. Formulations d'insuline à action ultrarapide stabilisées
TWI685348B (zh) * 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
US20180221385A1 (en) 2015-07-28 2018-08-09 Societe De Commercialisation Des Produits De La Recherche Appliquee Socpra Sciences Sante Et A pharmaceutical preparation for improving absorption and postprandial hypoglycemic action of insulin
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول

Also Published As

Publication number Publication date
PT3340966T (pt) 2022-12-05
JP2018172404A (ja) 2018-11-08
SV2018005643A (es) 2018-10-09
CR20180118A (es) 2018-03-20
WO2017034956A1 (fr) 2017-03-02
EP3340966B1 (fr) 2022-10-12
MY195781A (en) 2023-02-13
EP3340966A1 (fr) 2018-07-04
US20170056478A1 (en) 2017-03-02
ECSP18014922A (es) 2018-04-30
KR20180033276A (ko) 2018-04-02
US9901623B2 (en) 2018-02-27
DOP2018000059A (es) 2018-04-15
IL256939A (en) 2018-03-29
JP2018507869A (ja) 2018-03-22
US10925931B2 (en) 2021-02-23
RS63731B1 (sr) 2022-12-30
AR134413A2 (es) 2026-01-14
PH12018500422B1 (en) 2022-04-01
EP4169505A1 (fr) 2023-04-26
AU2016310475A1 (en) 2018-02-15
ZA201800511B (en) 2019-07-31
CA2994427C (fr) 2019-07-09
AU2016310475B2 (en) 2018-10-18
EA033396B1 (ru) 2019-10-31
MX2018002482A (es) 2018-06-15
CA2994427A1 (fr) 2017-03-02
PE20180782A1 (es) 2018-05-07
FI3340966T3 (fi) 2023-01-13
PH12018500422A1 (en) 2018-08-29
HUE060626T2 (hu) 2023-03-28
US20210169988A1 (en) 2021-06-10
BR112018001755A2 (pt) 2018-09-18
JO3749B1 (ar) 2021-01-31
US20180140676A1 (en) 2018-05-24
CO2018002026A2 (es) 2018-05-21
CN107920992B (zh) 2021-06-18
JP6359780B2 (ja) 2018-07-18
CN107920992A (zh) 2018-04-17
IL256939B (en) 2019-10-31
LT3340966T (lt) 2022-11-25
CL2018000503A1 (es) 2018-08-03
KR102018998B1 (ko) 2019-09-05
ES2928664T3 (es) 2022-11-21
AR105712A1 (es) 2017-11-01
PL3340966T3 (pl) 2023-01-30
MX379267B (es) 2025-03-11
DK3340966T3 (da) 2022-10-24
JP6935364B2 (ja) 2021-09-15
NZ739338A (en) 2019-06-28
TN2018000056A1 (en) 2019-07-08
MD3340966T2 (ro) 2023-04-30
MA42701A (fr) 2018-07-04
UA120142C2 (uk) 2019-10-10
TW201717997A (zh) 2017-06-01
TWI614025B (zh) 2018-02-11
EA201890343A1 (ru) 2018-07-31
HRP20221367T1 (hr) 2023-01-06

Similar Documents

Publication Publication Date Title
MA41188B1 (fr) Compositions d'insuline à action rapide
MX379267B (es) Composiciones de insulina de rapida accion.
MA39441A1 (fr) Composition d'insuline a action rapide
MA56049A (fr) Formulations stabilisées contenant des anticorps anti-angptl3
MA42678B1 (fr) Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5
PH12018501502A1 (en) Egf(a) analogues with fatty acid substituents
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
MA52309B1 (fr) Régulateurs de nrf2
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
MX385820B (es) Unidad de dosificacion orodispersable que contiene un componente estetrol.
EP3773900A4 (fr) Analogues d'hinokitiol, procédés de préparation et compositions pharmaceutiques de ceux-ci
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
PH12020551618A1 (en) Erenumab compositions and uses thereof
MY190102A (en) Tolerogenic dna vaccine
MX2022006502A (es) Composiciones farmaceuticas.
EP3399040A4 (fr) Procédé de préparation d'une protéine de capside de circovirus porcin de type 2 et composition pharmaceutique la contenant
MA39272A (fr) Formulations à libération prolongée de gabapentine
JOP20190277B1 (ar) تركيبات إنسولين سريعة المفعول
BR112022023738A2 (pt) Formulação líquida
MA55298A (fr) Compositions pharmaceutiques contenant des anticorps anti-lingo-1
TH168567A (th) องค์ประกอบอินซูลินออกฤทธิ์รวดเร็ว
TH170460A (th) องค์ประกอบเภสัชภัณฑ์สำหรับการให้ทางปากซึ่งประกอบรวมด้วยแทกเซน
TN2014000127A1 (fr) Composition pharmaceutique effervescente a desagregation rapide a base de prednisolone metasulfobenzoate et son procede de fabrication